Amgen recently announced top-line results from a phase 3 clinical trial that sought to evaluate the safety and efficacy of its proposed infliximab biosimilar, ABP 710, compared with the reference product (Remicade) in patients with moderate-to-severe rheumatoid arthritis (RA).
Amgen recently announced top-line results from a phase 3 clinical trial that sought to evaluate the safety and efficacy of its proposed infliximab biosimilar, ABP 710, compared with the reference product (Remicade) in patients with moderate-to-severe rheumatoid arthritis (RA).
The randomized double-blind study enrolled 558 and randomized (1:1) 558 patients with RA to receive either ABP 710 or reference infliximab at a dose of 3 mg/kg infused on day 1, at weeks 2 and 6, and every 8 weeks thereafter. The ABP 710 arm, as well as the reference infliximab arm, were equally comprised of 279 patients.
The primary end point of the study was achieving 20% or greater improvement as defined by the American College of Rheumatology criteria (ACR20) at week 22. Secondary endpoints included achieving ACR50, ACR70, and disease activity score 28-joint count C reactive protein (DAS28-CRP).
Researchers confirmed the noninferiority of ABP 710 compared with infliximab, but “could not rule out superiority based on its primary efficacy endpoint,” according to the news release. Notably, the DAS28-CRP difference in mean change from the baseline was close to 0, at —0.01 (95% CI, –0.20 to 0.17). In addition, the safety profile and immunogenicity were comparable between ABP 710 and the originator.
“We believe this study confirms no clinically meaningful differences between ABP 710 and [reference] infliximab. Biosimilars are approved based on the analytical, nonclinical, and clinical data, and we believe that the totality of the evidence we’ve generated supports ABP 710 as highly similar to the reference product,” said Sean Harper, MD, executive vice president of research and development at Amgen in a statement.
Amgen is also working on the development of a number of other biosimilar products, including ABP 494, biosimilar cetuximab; ABP 798, biosimilar rituximab; ABP 959, biosimilar eculizumab, and Kanjinti, a trastuzumab biosimilar that was authorized for marketing in Europe in May 2018, 1 day after it was announced that the FDA had issued a Complete Response Letter for the same product.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.